Last reviewed · How we verify

Polatuzumab, bendamustin und rituximab

Medical University of Vienna · Phase 2 active Small molecule Quality 0/100

Polatuzumab, bendamustin und rituximab is a Small molecule drug developed by Medical University of Vienna. It is currently in Phase 2 development. Also known as: Polivy, Bendamustin, Mabthera.

At a glance

Generic namePolatuzumab, bendamustin und rituximab
Also known asPolivy, Bendamustin, Mabthera
SponsorMedical University of Vienna
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Polatuzumab, bendamustin und rituximab

What is Polatuzumab, bendamustin und rituximab?

Polatuzumab, bendamustin und rituximab is a Small molecule drug developed by Medical University of Vienna.

Who makes Polatuzumab, bendamustin und rituximab?

Polatuzumab, bendamustin und rituximab is developed by Medical University of Vienna (see full Medical University of Vienna pipeline at /company/medical-university-of-vienna).

Is Polatuzumab, bendamustin und rituximab also known as anything else?

Polatuzumab, bendamustin und rituximab is also known as Polivy, Bendamustin, Mabthera.

What development phase is Polatuzumab, bendamustin und rituximab in?

Polatuzumab, bendamustin und rituximab is in Phase 2.

Related